An examination of a marijuana "infrastructure play," its rivals, whether it's overpriced or underpriced, and a prediction for the stock in 2019. Read More

The last few years have been rough for biotech stocks, but Amgen has been a notable exception. It's now facing new threats from biosimilars. Can it continue to outperform? Read More

This mid-cap biotech is developing novel drugs for diseases that resist conventional therapies. Is Arena a future "rocket stock" or will it blow up on the launch pad? Read More

This cannabis biotech is a micro-cap garnering Wall Street's attention. As investors flock to pot investments, is United Cannabis an appealing play or risky penny stock? Read More

Hemp (OTC: HEMP) uses the sturdy fibers of the hemp plant to create industrial products. Is this "picks-and-shovels" cannabis play a worthy investment or risky penny stock? Read More

This maker of cannabis-related recreational and medical products enjoys tailwinds as cannabis legalization continues apace. But is it an overly risky penny stock? Read More

Is this cannabis company a viable enterprise or just another penny stock booby trap? We examine whether Abattis is a small-cap value play or toxic investment. Read More

Penny stocks and the marijuana industry: the combination is a Siren’s Call that could bring you fast gains. Or wreck your portfolio. Which brings us to PotNetwork Holdings (OTC: POTN), a small cannabis firm that has come under widespread scrutiny lately. PotNetwork Holdings aspires to be many things. When you… Read More

Microsoft (NSDQ: MSFT) is not the company it once was. And that’s a good thing. This technology icon is an example of how a great company can lose its way and then reinvent itself to become stronger than ever. Back in 2000, the dot.com bubble burst and the technology sector… Read More

Americans spend $9,523 per person a year on medical expenses, by far the most among developed countries. Annual spending in the U.S. on health services now exceeds $3 trillion a year. Those eye-opening statistics come courtesy of the private, nonpartisan research group the Commonwealth Fund. Think of this spending… Read More